Beta thalassemia gene therapy using lentiviral vectors

Authors

  • Abbasalipour, Maryam PhD of Medical Biotechnology, Department of Molecular Medicine, Pasteur Institute of Tehran, Tehran, Iran
  • Khosravi, Mohammad Ali PhD of Medical Biotechnology, Department of Molecular Medicine, Pasteur Institute of Tehran, Tehran, Iran
  • Zeinali, Sirous Department of Molecular Medicine, Pasteur Institute of Iran, Tehran, Tehran, Iran
Abstract:

Recent years, allogeneic bone marrow transplantation (BMT) has proved to be the successful cure for patients with thalassemia major, however this is restricted due to limited matched-related donor. Its complications include chronic graft-versus-host disease in 5-8% of patients. So, a molecular approach, such as gene therapy for direct normal beta globin gene transmission, seems quite promising to cure thalassemia. The goal of beta thalassemia gene therapy is to restore normal RBC production capacity in patients by suitable vector and correct inherited anemia. Virus therapy has recently been recognized as a promising new therapeutic approach in medical research. In this regard, the use of viruses as non-replicating gene therapy vectors or as replication viruses (oncolytic viruses) has provided attractive opportunities for viral therapy applications. Currently viral vectors have been used in nearly 70% of the clinical trials. In recent years, many researchers have designed erythroid-specific lentiviral vectors carrying the beta-globin gene that have obtained significant results. Their findings are presented in this study.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Evaluation of the Efficacy of Lentiviral Vectors in Gene Therapy of Beta-thalassemia Patients: A Systematic Review

Background Beta thalassemiais a genetic blood abnormality identified through mutations, which reduce the synthesis of the ß-globin chain. Gene therapy through Lentiviral vectors have cured many of genetic disorders. The purpose of this study was to investigate the efficacy of lentiviral vectors in treatment of ß-thalassemia a...

full text

Lentiviral vectors and gene therapy.

Gene therapy is a novel method under investigation for the treatment of genetic, metabolic and neurologic diseases, cancer and AIDS. The primary goal of gene therapy is to deliver a specific gene to a pre-determined target cell, and to direct expression of such a gene in a manner which will result in a therapeutic effect. Retroviral vectors have the ability to integrate in the host cell DNA irr...

full text

Lentiviral Vectors and Cystic Fibrosis Gene Therapy

Cystic fibrosis (CF) is a chronic autosomic recessive syndrome, caused by mutations in the CF Transmembrane Conductance Regulator (CFTR) gene, a chloride channel expressed on the apical side of the airway epithelial cells. The lack of CFTR activity brings a dysregulated exchange of ions and water through the airway epithelium, one of the main aspects of CF lung disease pathophysiology. Lentivir...

full text

Lentiviral Vectors: Not Just For Gene Therapy

Lentiviral vectors (LVs) are viral-based gene delivery systems that can stably deliver genes or RNAi into primary cells or cell lines with up to 100% efficiency. LVs bind to target cells using an envelope protein which allows for release of the LV RNA containing the gene or gene silencing sequence into the cell. The LV’s RNA is then converted into DNA using an enzyme called reverse transcriptas...

full text

Gene therapy of Fanconi anemia: preclinical efficacy using lentiviral vectors.

Fanconi anemia (FA) is an inherited cancer susceptibility syndrome caused by mutations in a DNA repair pathway including at least 6 genes (FANCA, FANCC, FANCD2, FANCE, FANCF, and FANCG). The clinical course of the disease is dominated by progressive, life-threatening bone marrow failure and high incidence of acute myelogenous leukemia and solid tumors. Allogeneic bone marrow transplantation (BM...

full text

Gene therapy for neurodegenerative and ocular diseases using lentiviral vectors.

Gene therapy holds great promise for the treatment of a wide range of inherited and acquired disorders. The development of viral vector systems to mediate safe and long-lasting expression of therapeutic transgenes in specific target cell populations is continually advancing. Gene therapy for the nervous system is particularly challenging due to the post-mitotic nature of neuronal cells and the ...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 30  issue 4

pages  341- 351

publication date 2020-12

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

No Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023